Glossary of Terms – Healthcare organization (HCO) refers to a system comprised of people, facilities, and resources that deliver healthcare services to patients. Healthcare personnel (HCP) refers to all paid and unpaid persons serving in healthcare settings who have the potential for direct or indirect exposure to patients or infectious materials, including body substances (e.g., blood, tissue, and specific body fluids); contaminated medical supplies, devices, and equipment; contaminated environmental surfaces; or contaminated air.
These HCP may include, but are not limited to, emergency medical service personnel, nurses, nursing assistants, physicians, technicians, therapists, phlebotomists, pharmacists, students and trainees, contractual staff not employed by the health care facility, and persons (e.g., clerical, dietary, environmental services, laundry, security, maintenance, engineering and facilities management, administrative, billing, and volunteer personnel) not directly involved in patient care but potentially exposed to infectious agents that can be transmitted among from HCP and patients.
For this update, HCP does not include dental healthcare personnel, autopsy personnel, and laboratory personnel, as recommendations to address occupational infection prevention and control (IPC) services for these personnel are posted elsewhere, Healthcare settings refers to places where healthcare is delivered and includes, but is not limited to, acute care facilities, long term acute care facilities, inpatient rehabilitation facilities, nursing homes and assisted living facilities, home healthcare, vehicles where healthcare is delivered (e.g., mobile clinics), and outpatient facilities, such as dialysis centers, physician offices, and others.
- Occupational Health Services (OHS) refers to the group, department, or program that addresses many aspects of health and safety in the workplace for HCP, including the provision of clinical services for work-related injuries, exposures, and illnesses.
- In healthcare settings, OHS addresses workplace hazards including communicable diseases; slips, trips and falls; patient handling injuries; chemical exposures; HCP burnout; and workplace violence.
In this document, the term OHS is used synonymously with “Employee Health,” “Employee Health Services,” “Employee Health and Safety,” “Occupational Health,” and other such programs. Occupational infection prevention and control (IPC) services refers to a subset of services provided by occupational health services for preventing the transmission of infectious illnesses in the workplace.
- Performance measures refer to objective, quantitative indicators of various aspects of the performance of a program.
- They can focus on different aspects of performance, such as effectiveness, efficiency, productivity, cost effectiveness, or customer satisfaction,
- Presenteeism refers to the act of attending work while ill and potentially infectious to others.
Quality improvement refers to a continuous and ongoing effort to achieve measurable improvements in the efficiency, effectiveness, performance, accountability, outcomes, and other indicators of quality in services, Safety culture of an organization refers to the product of individual and group values, attitudes, perceptions, competencies, and patterns of behavior that determine the commitment to an organization’s health and safety management.
What does HCP stand for in medical terms?
Healthcare proxy. A type of advance directive that gives a person (such as a relative, lawyer, or friend) the authority to make healthcare decisions for another person. It becomes active when that person loses the ability to make decisions for himself or herself. Also called health care proxy.
What is the purpose of a HCP?
Collaborating on clinical trials and research – Healthcare professionals (HCPs) help us identify potential volunteers for clinical trials, administer the investigational medicine or vaccine to patients, and monitor the results. All HCPs who work with us on clinical trials have contracts and are paid for their work on these clinical trials.
Argentina As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services. In 2021, GSK made payments totaling ARS 22.505.278,81 to a total of 143 healthcare professionals.
| Year | Report |
|---|---|
| 2021 | PDF (235KB) |
Media enquiries: Please contact Daniel Morelli, Comms & Government Affairs Manager
| Contact details | |
|---|---|
| Email: | [email protected] |
Austria As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Deutsch |
|---|---|---|---|
| 2021 | PDF (204KB) | PDF (751KB) | PDF (656KB) |
| 2020 | PDF (1.7MB) | PDF (116KB) | PDF (97KB) |
| 2019 | PDF (139KB) | PDF (119KB) | PDF (101KB) |
Media enquiries: Please contact Mag. Barbara Masser-Mayerl, Communications Manager
| Contact details | |
|---|---|
| Tel: | +43 664 8270120 |
| Email: | [email protected] |
Bahrain GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services.
| Year | Report |
|---|---|
| 2021 | PDF (226KB) |
Media enquiries: Please contact Averyan Vasylyev, Medical Director
| Contact details | |
|---|---|
| Tel: | +971 564014498 |
| Email: | [email protected] |
Belgium As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number. The links below will take you to our disclosures for Belgium in line with the EFPIA code and pharma.be code, and to a note on the methodology used to set out the data in the report.
Consult the register The significant presence of GSK Vaccines in Belgium, where the global centre for R&D (research & development) as well as the manufacturing site of vaccines, explain why some local collaborations with Healthcare Professionals and Organisations have an international dimension.
| Contact details | |
|---|---|
| Tel: | +32 478 27 26 41 |
| Email: | [email protected] |
Bosnia and Herzegovina As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Bosnian |
|---|---|---|---|
| 2021 | No transfer of values were made | ||
| 2020 | No transfer of values were made | ||
| 2019 | PDF (83KB) | PDF (147KB) |
Media enquiries: Please contact Office Headquarters
| Contact details | |
|---|---|
| Email: | [email protected] |
Brazil GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services.
| Contact details | |
|---|---|
| Email: | [email protected] |
Bulgaria As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note |
|---|---|---|---|
| 2021 | PDF (116KB) | PDF (104KB) | PDF (102KB) |
| 2020 | PDF (142KB) | PDF (272KB) | PDF (119KB) |
| 2019 | PDF (135KB) | PDF (272KB) | PDF (121KB) |
Media enquiries: Please contact Office Headquarters
| Contact details | |
|---|---|
| Email: | [email protected] |
Chile GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services.
| Year | Report |
|---|---|
| 2021 | PDF (199KB) |
Media enquiries: Please contact Mariella Parodi Soza, Communications & Government Affairs Head, LATAM South Pacific Cluster
| Contact details | |
|---|---|
| Tel: | +56 954023957 |
| Email: | [email protected] |
Colombia GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services.
GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices. In 2021, we have paid COP 160.733.320* to a total number of 30 HCPs with an average payment of COP 5.357.777/HCP. * This amount does not include Colombian HCPs hired by other GSK subsidiaries and paid outside Colombia.
Media enquiries: Please contact Juan Garcia, CGA Colombia Head
| Contact details | |
|---|---|
| Tel: | +57 3243457682 |
| Email: | [email protected] |
Croatia As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Hrvatski |
|---|---|---|---|
| 2021 | PDF (103KB) | PDF (105KB) | PDF (103KB) |
| 2020 | PDF (118KB) | PDF (125KB) | PDF (171KB) |
| 2019 | PDF (139KB) | PDF (201KB) | PDF (227KB) |
Media enquiries: Please contact Office Headquarters
| Contact details | |
|---|---|
| Email: | [email protected] |
Cyprus As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English |
|---|---|---|
| 2021 | No transfer of values were made | |
| 2020 | PDF (97KB) | PDF (98KB) |
| 2019 | PDF (100KB) | PDF (98KB) |
Media enquiries: Please contact Office Headquarters
| Contact details | |
|---|---|
| Email: | [email protected] |
Czech Republic As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Czech |
|---|---|---|---|
| 2021 | PDF (157KB) | PDF (21KB) | PDF (65KB) |
| 2020 | PDF (129KB) | PDF (23KB) | PDF (71KB) |
| 2019 | PDF (140KB) | PDF (23KB) | PDF (72KB) |
Media enquiries: Please contact Miriam Kejzlarová, Communication Manager
| Contact details | |
|---|---|
| Email: | [email protected] |
Denmark As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number. EFPIA has assessed the Danish legislation on disclosure (decree number L94/2013-14) to meet the requirements for transparency and has exempted Denmark from implementing the EFPIA Disclosure Code given the disclosures are already disclosed through the Danish Medicines Agency / Laegemiddelstyrelsen.
Legislation in Denmark requires HCPs to self-disclose:
Any engagement with a pharmaceutical company including zero payment engagements All R&D engagements by named disclosure Congress sponsorships (no amount disclosure)
Our disclosures in Denmark via Danish Medicines Agency / Laegemiddelstyrelsen include all transfers of value made by GSK to individual HCPs. Any payments to HCOs and hospitals in Denmark are disclosed on the Grants & Donations section on GSKPro and in a yearly report on the homepage of ENLI (The Ethical Comittee for the Pharmaceutical Industry).
| Contact details | |
|---|---|
| Email: | [email protected] |
Estonia As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Eesti |
|---|---|---|---|
| 2021 | PDF (99KB) | PDF (118KB) | PDF (97KB) |
| 2020 | PDF (102KB) | PDF (551KB) | PDF (487KB) |
| 2019 | PDF (111KB) | PDF (283KB) | PDF (557KB) |
Media enquiries: Please contact Head Office
| Contact details | |
|---|---|
| Email: | [email protected] |
Finland As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Suomeksi |
|---|---|---|---|
| 2021 | PDF (175KB) | PDF (145KB) | PDF (143KB) |
| 2020 | PDF (161KB) | PDF (130KB) | PDF (129KB) |
| 2019 | PDF (153KB) | PDF (166KB) | PDF (153KB) |
Media enquiries: Please contact Anna Dammert
| Contact details | |
|---|---|
| Tel: | + 358 10 3030401 |
| Email: | [email protected] |
France As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Français |
|---|---|---|---|
| 2021 | PDF (94KB) | PDF (99KB) | PDF (118KB) |
| 2020 | PDF (92KB) | PDF (102KB) | PDF (82KB) |
| 2019 | PDF (87KB) | PDF (112KB) | PDF (95KB) |
Media enquiries: Please contact Victoria Morel, Media Communication Manager
| Contact details | |
|---|---|
| Tel: | + 33 139178538 |
| Email: | [email protected] |
Germany As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Deutsch |
|---|---|---|---|
| 2021 | PDF (514KB) | PDF (153KB) | PDF (157KB) |
| 2020 | PDF (441KB) | PDF (498KB) | PDF (50KB) |
| 2019 | PDF (471KB) | PDF (49KB) | PDF (50KB) |
Media enquiries: Please contact Dr. med. Guido Hermanns, Head of Communications
| Contact details | |
|---|---|
| Tel: | + 49 89 360448643 |
| Email: | [email protected] |
Greece As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Ελληνικά |
|---|---|---|---|
| 2021 | PDF (413KB) | PDF (193KB) | PDF (187KB) |
| 2020 | PDF (268KB) | PDF (132KB) | PDF (125KB) |
| 2019 | PDF (277KB) | PDF (164KB) | PDF (154KB) |
Media enquiries: Please contact Vasilia Papagiannopoulou – Government Affairs & Market Access Director
| Contact details | |
|---|---|
| Tel: | + 30 210 6882170 |
| Email: | [email protected] |
Hungary As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Magyar |
|---|---|---|---|
| 2021 | PDF (107KB) | PDF (87KB) | PDF (108KB) |
| 2020 | PDF (120KB) | PDF (90KB) | PDF (107KB) |
| 2019 | PDF (120KB) | PDF (88KB) | PDF (116KB) |
Media enquiries: Please contact Office Headquarters
| Contact details | |
|---|---|
| Email: | [email protected] |
Kuwait GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services.
| Year | Report |
|---|---|
| 2021 | PDF (231KB) |
Media enquiries: Please contact Averyan Vasylyev, Medical Director
| Contact details | |
|---|---|
| Tel: | +971 564014498 |
| Email: | [email protected] |
Ireland As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number. The link below will take you to our disclosures for Ireland in line with the EFPIA code and Irish Pharmaceutical Healthcare Association (IPHA) code, that we are making through IPHA.
http://www.transferofvalue.ie/ Media enquiries: Please contact Niamh Mullen, Head of Communications and Government Affairs
| Contact details | |
|---|---|
| Tel: | +353 873516294 |
| Email: | [email protected] |
Israel As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English |
|---|---|---|
| 2021 | PDF (77KB) | PDF (112KB) |
| 2020 | PDF (120KB) | PDF (29KB) |
| 2019 | PDF (32KB) | PDF (79KB) |
Media enquiries: Please contact Margalit Keren, Communications Manager
| Contact details | |
|---|---|
| Email: | [email protected] |
Italy As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Italiano |
|---|---|---|---|
| 2021 | PDF (843KB) | PDF (121KB) | PDF (102KB) |
| 2020 | PDF (1.2MB) | PDF (120KB) | PDF (102KB) |
| 2019 | PDF (1.4MB) | PDF (114KB) | PDF (96KB) |
Media enquiries: Please contact Massimo Ascani, External Communications Director
| Contact details | |
|---|---|
| Email: | [email protected] |
Latvia As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number. Please find latest local disclosure report combining data from different companies published by Latvian Health Inspectorate. A distributor SIA TAMRO (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Latvia.
GSK has given authorisation for SIA TAMRO (“Phoenix”) to report Transfers of Value made to HCPs / HCOs in Latvia by GSK and by ViiV Healthcare. The links below will take you to our previous year’s disclosures for Latvia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Latviski |
|---|---|---|---|
| 2021 | Transfers of value available on the Latvian Health Inspectorate | ||
| 2020 | Transfers of value available on the Latvian Health Inspectorate | ||
| 2019 | PDF (113KB) | PDF (106KB) | PDF (142KB) |
Media enquiries: Please contact Office Headquarters
| Contact details | |
|---|---|
| Email: | [email protected] |
Lithuania As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number. New local disclosure report will be published on State Medicines Control Agency Lithuania website by August 1, 2022 for ToVs to HCPs, and by November 1, 2022 for ToVs to HCOs.
A distributor UAB „Tamro” (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Lithuania. GSK has given authorisation for UAB TAMRO (“Phoenix”) to report Transfers of Value made to HCPs / HCOs in Lithuania by GSK and by ViiV Healthcare.
| Year | Report | Methodological Note English | Methodological Note Lietuvos |
|---|---|---|---|
| 2021 | PDF (158KB) | PDF (125KB) | PDF (93KB) |
| 2020 | Transfers of value available on the State Medicines Control Agency Lithuania website | PDF (123KB) | PDF (89KB) |
| 2019 | PDF (114KB) | PDF (106KB) | PDF (160KB) |
R&D aggregate TOV report:
| Year | EFPIA Research Aggregate Disclosure Report |
|---|---|
| 2021 | PDF (92KB) |
| 2020 | PDF (93KB) |
Media enquiries: Please contact Office Headquarters
| Contact details | |
|---|---|
| Email: | [email protected] |
Luxembourg As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number. The links below will take you to our disclosures for Luxembourg in line with the EFPIA code and APL code, and to a note on the methodology used to set out the data in the report.
Consult the register
| Year | Report | Methodological Note English | Methodological Note Français |
|---|---|---|---|
| 2021 | PDF (96KB) | PDF (176KB) | PDF (101KB) |
| 2020 | PDF (98KB) | PDF (96KB) | PDF (101KB) |
| 2019 | PDF (99KB) | PDF (94KB) | PDF (98KB) |
Media enquiries: Please contact Elisabeth Van Damme
| Contact details | |
|---|---|
| Tel: | +32 478 27 26 41 |
| Email: | [email protected] |
Malaysia GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending / supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services.
| Year | Report |
|---|---|
| 2021 | PDF (102KB) |
Media enquiries: Please contact David Lin, Director, Communications, Government Affairs & Strategic Customer Solutions
| Contact details | |
|---|---|
| Email: | [email protected] |
Malta As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English |
|---|---|---|
| 2021 | No transfer of values were made | |
| 2020 | PDF (89KB) | PDF (92KB) |
| 2019 | PDF (90KB) | PDF (92KB) |
Media enquiries: Please contact Central Office
| Contact details | |
|---|---|
| Email: | [email protected] |
Mexico GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services.
| Contact details | |
|---|---|
| Tel: | + 55 54835200 |
| Email: | [email protected] |
Netherlands As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number. The links below will take you to our disclosures for the Netherlands in line with the EFPIA code and Code for Pharmaceutical Advertising (the CGR), and to a note on the methodology used to set out the data in the report.
Transfers of value for research and development are not part of the Transparency Register and is therefore listed separately for GSK Netherlands. https://www.transparantieregister.nl/homepage/zoek-uw-zorgaanbieder
| Year | EFPIA Research Aggregate Disclosure Report |
|---|---|
| 2021 | PDF (11KB) |
| 2020 | PDF (11KB) |
| 2019 | PDF (11KB) |
Media enquiries: Please contact Central Office
| Contact details | |
|---|---|
| Tel: | +31 (0) 6 13 51 11 88 |
North Macedonia As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report |
|---|---|
| 2021 | No transfer of values were made |
| 2020 | No transfer of values were made |
| 2019 | No transfer of values were made |
Media enquiries: Please contact Central Office
| Contact details | |
|---|---|
| Email: | [email protected] |
Norway As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Norsk |
|---|---|---|---|
| 2021 | PDF (172KB) | PDF (103KB) | PDF (117KB) |
| 2020 | PDF (170KB) | PDF (104KB) | PDF (104KB) |
| 2019 | PDF (124KB) | PDF (101KB) | PDF (102KB) |
Media enquiries: Please contact Line Storesund Rondan, Head of Government Affairs and Communication
| Contact details | |
|---|---|
| Tel: | +47 227 02 000 |
| Email: | [email protected] |
Oman GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services.
| Year | Report |
|---|---|
| 2021 | PDF (220KB) |
Media enquiries: Please contact Averyan Vasylyev, Medical Director
| Contact details | |
|---|---|
| Tel: | +971 564014498 |
| Email: | [email protected] |
Philippines GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our transfer of values to HCPs includes scientific sponsorships and honorariums for provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services.
GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices. In 2021, we paid a total of Php 911.4k to 31 HCPs. Disclaimer: This is a demonstration of GSK’s transparency commitments as a global organization based on its independent selection of in scope activities.
As such, the values herein disclosed may vary from GSK Philippines Inc.’s declaration in compliance with the local legal disclosure requirements. Further, no data privacy rights of any HCP has been breached by the foregoing disclosure. Media enquiries: Please contact Richard Arboleda, Communications and Government Affairs Head
| Contact details | |
|---|---|
| Tel: | +632 88920761 |
| Email: | [email protected] |
Poland As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Polski |
|---|---|---|---|
| 2021 | PDF (260KB) | PDF (632KB) | PDF (640KB) |
| 2020 | PDF (232KB) | PDF (632KB) | PDF (640KB) |
| 2019 | PDF (194KB) | PDF (628KB) | PDF (636KB) |
Media enquiries: Please contact Urszula Karniewicz
| Contact details | |
|---|---|
| Tel: | +48 504 144 704 |
| Email: | [email protected] |
Portugal As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number. In Portugal, GSK strictly complies with the requirements of Portuguese national law (decree number 176/2006) to continuously publish details of all transfers of value with HCOs and HCPs within 30 working days after any payment is made.
These disclosures are published and publicly available on the transparency website of Infarmed (Portugal‘s National Authority of Medicines and Health Products / Infarmed – Autoridade Nacional do Medicamento e Produtos de Saúde). Our disclosures in Portugal via Infarmed include all transfers of value made by GSK to individual HCPs as well as HCOs as required under Portuguese national law.
| Contact details | |
|---|---|
| Tel: | +351 918699965 |
| Email: | [email protected] |
Qatar GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services.
| Year | Report |
|---|---|
| 2021 | PDF (226KB) |
Media enquiries: Please contact Averyan Vasylyev, Medical Director
| Contact details | |
|---|---|
| Tel: | +971 564014498 |
| Email: | [email protected] |
Romania As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number. The links below will take you to our disclosures for Romania in line with the EFPIA code and the local legislation requirements as were specified in the Law no.95/2006 and OMS 194/2015.
Transfers of value to healthcare professionals and organisations published on the ANMDMR website as per Law no.95/2006 and OMS 194/2015: A distributor EL PHARMA ROMANIA SRL (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Romania.
| Year | EFPIA Research Aggregate Disclosure Report |
|---|---|
| 2021 | PDF (90KB) |
| 2020 | PDF (98KB) |
| 2019 | PDF (98KB) |
Media enquiries: Please contact Central Office
| Contact details | |
|---|---|
| Email: | [email protected] |
Russia As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note P |
|---|---|---|---|
| 2021 | PDF (209KB) | PDF (81KB) | PDF (141KB) |
| 2020 | PDF (159KB) | PDF (81KB) | PDF (141KB) |
| 2019 | PDF (209KB) | PDF (81KB) | PDF (141KB) |
Media enquiries: Please contact Ekaterina Zamaratskikh
| Contact details | |
|---|---|
| Email: | [email protected] |
Saudi Arabia GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/supporting educational meetings, providing advice as a member of an advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
| Contact details | |
|---|---|
| Tel: | +966 126536600 |
| Email: | [email protected] |
Serbia and Montenegro As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Srpski |
|---|---|---|---|
| 2021 | PDF (106KB) | PDF (104KB) | PDF (113KB) |
| 2020 | PDF (111KB) | PDF (122KB) | PDF (161KB) |
| 2019 | PDF (333KB) | PDF (145KB) | PDF (140KB) |
Media enquiries: Please contact Central Office
| Contact details | |
|---|---|
| Email: | [email protected] |
Slovakia As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
- Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
- The links below will take you to our disclosures for Slovakia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
- A distributor PHOENIX Zdravotnicke zasobovanie, a.s.
(“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Slovakia. Transfers of Value made to HCPs / HCOs are reported separately by the local Phoenix entity on https://www.nczisk.sk and should be considered together with transfers of value made by GSK directly.
| Year | Report | Methodological Note English | Methodological Note Slovak |
|---|---|---|---|
| 2021 | PDF (101KB) | PDF (125KB) | PDF (153KB) |
| 2020 | PDF (103KB) | PDF (71KB) | PDF (127KB) |
| 2019 | PDF (104KB) | PDF (73KB) | PDF (130KB) |
Media enquiries: Please contact Central Office
| Contact details | |
|---|---|
| Email: | [email protected] |
Slovenia As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Slovenščina |
|---|---|---|---|
| 2021 | PDF (101KB) | PDF (105KB) | PDF (104KB) |
| 2020 | PDF (1.5MB) | PDF (88KB) | PDF (99KB) |
| 2019 | PDF (116KB) | PDF (88KB) | PDF (99KB) |
Media enquiries: Please contact Central Office
| Contact details | |
|---|---|
| Email: | [email protected] |
Spain As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Español |
|---|---|---|---|
| 2021 | PDF (3.6MB) | PDF (110KB) | PDF (109KB) |
| 2020 | PDF (3.2MB) | PDF (109KB) | PDF (108KB) |
| 2019 | PDF (1.8MB) | PDF (117KB) | PDF (112KB) |
Media enquiries: Please contact Comms Department
| Contact details | |
|---|---|
| Email: | [email protected] |
Sweden As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Svenska |
|---|---|---|---|
| 2021 | PDF (160KB) | PDF (110KB) | PDF (334KB) |
| 2020 | PDF (117KB) | PDF (111KB) | PDF (334KB) |
| 2019 | PDF (118KB) | PDF (111KB) | PDF (111KB) |
Media enquiries: Please contact Håkan Sjöström, Medical Governance Manager
| Contact details | |
|---|---|
| Tel: | +46 70 6628 608 |
| Email: | [email protected] |
Switzerland As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English | Methodological Note Deutsch | Methodological Note Français |
|---|---|---|---|---|
| 2021 | PDF (195KB) | PDF (241KB) | PDF (251KB) | PDF (243KB) |
| 2020 | PDF (179KB) | PDF (30KB) | PDF (32KB) | PDF (32KB) |
| 2019 | PDF (175KB) | PDF (51KB) | PDF (52KB) | PDF (51KB) |
Media enquiries: Please contact Urs Kientsch, Corporate Affairs Director or Manuel Mosimann, Communications Manager
| Contact details | |
|---|---|
| Tel: | +41 (0) 79 292 56 91 +41 (0) 79 948 43 51 |
| Email: | [email protected] [email protected] |
Thailand GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services.
- GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
- In 2021, we have paid 102,639 GBP to a total number of 654 HCPs* with an average payment of 157 GBP/HCP.
- There might be duplication due to independent sponsorships.
Media enquiries: Please contact Supattra Harncharoen, Corporate Affairs Manager
| Contact details | |
|---|---|
| Tel: | +66 886641188 |
| Email: | [email protected] |
Turkey We have pledged to disclose the transfer of value that we make as we work together with healthcare professionals. This includes services such as speaker service, participation / support in educational meetings, participation in the Advisory Board or Consulting, as well as accommodation and transportation costs associated with these services.
At GSK, our decision to voluntarily publish the payments we pay to HCPs is part of our commitment to ensuring our high ethical standards and transparency in the conduct of our business. In 2021, we paid 11,972,953.78 (TL) totally to the 1745 (number of HCPs) HCPs, and our average payment per Healthcare Professional was 6,861.29 (TL).
Media enquiries: Please contact Zeynep Birgül, Brand Communications & Patient Relations Manager
| Contact details | |
|---|---|
| Tel: | +90 5307887733 |
| Email: | [email protected] |
Ukraine As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English |
|---|---|---|
| 2021 | Disclosure suspended for 2021 | |
| 2020 | PDF (109KB) | PDF (126KB) |
| 2019 | PDF (112KB) | PDF (126KB) |
Media enquiries: Please contact Tetiana Tkachenko, Tender and Price Manager, GSK Pharmaceuticals Ukraine or Maryna Kuzemko, 180 PRPA or Anna Dziuba, 180 PRPA
| Contact details | |
|---|---|
| Tel: | +380504698305 +380503876389 +380504124721 |
| Email: | [email protected] [email protected] [email protected] |
United Arab Emirates GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services.
| Year | Report |
|---|---|
| 2021 | PDF (292KB) |
Media enquiries: Please contact Averyan Vasylyev, Medical Director
| Contact details | |
|---|---|
| Tel: | +971 564014498 |
| Email: | [email protected] |
United Kingdom As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs.
| Year | Report | Methodological Note English |
|---|---|---|
| 2021 | PDF (701KB) | PDF (149KB) |
| 2020 | PDF (613KB) | PDF (64KB) |
| 2019 | PDF (816KB) | PDF (187KB) |
Media enquiries: Please contact UK Office
| Contact details | |
|---|---|
| Email: | [email protected] |
/ul>
What is a HCP in pharma?
What is the Role of HCP In Driving Pharma Marketing? The role of HCP in driving Pharma Marketing is very significant. HCPs (Health Care Professionals) are the primary target of pharmaceutical companies when it comes to pharma hcp marketing, All the healthcare professionals in the field have a common goal: improving patient outcomes.
This is where these companies step in by providing authoritative, clear and valuable materials that they can share further with their patients. HCPs have the authority by law to write a prescription, which allows a patient to get the required medicine from a pharma store. So, they are enabled with the prescription power, and if you pitch them with your product in the proper manner, the chances that they’ll prescribe your product increases to the bar of very high.
Focused, targeted marketing campaigns attract the attention of HCPs in spreading the word about new pharmaceutical products and services and is a valuable, integral part of any company’s initiatives. So, HCPs carry a lot of value with them.
Does HCP mean a physician?
Healthcare Provider or Healthcare Practitioner (HCP means a licensed medical doctor, licensed medical professional, medical institution, medical facility, hospital or clinic whose core endeavor is to provide medical services to patients and is legally licensed for such activities.
What is HCP and HCO?
The relationship with healthcare professionals (HCPs) and healthcare organisations (HCOs) takes on various forms: development of new drugs through clinical studies at hospitals, universities, and public and private health facilities, but also scientific advice, conferences, seminars and CME (Continuing Medical
What does HPC stand for?
High Performance Computing most generally refers to the practice of aggregating computing power in a way that delivers much higher performance than one could get out of a typical desktop computer or workstation in order to solve large problems in science, engineering, or business.
High Performance Computing most generally refers to the practice of aggregating computing power in a way that delivers much higher performance than one could get out of a typical desktop computer or workstation in order to solve large problems in science, engineering, or business. Scientist need HPC because they hit a tipping point.
At some point in research, there is a need to:
Expand the current study area (regional → national → global) Integrate new data Increase model resolution
But processing on my desktop or a single server no longer works Some typical computational barriers:
Time – processing on local systems is too slow or not feasible CPU Capacity – Can only run one model at a time Develop, implement, and disseminate state-of-the-art techniques and tools so that models are more effectively applied to today’s decision-making Management of Computer Systems – Science Groups don’t want to purchase and manage local computer systems – they want to focus on science
“I need to do multiple sampling events of multiple simulations. No way can my existing system pull that off in a timely fashion, if at all.” ~David Warner, Research Fisheries, Biologist “We had an 80 node cluster here in Golden several years ago, but when I left for Memphis, nobody wanted to manage it.
Each different computer is called a node Each node has processors/cores
Carry out the instructions of the computer
With a supercomputer, all these different computers talk to each other through a communications network
Example – InfiniBand
Supercomputers give you the opportunity to solve problems that are too complex for the desktop. It might take hours, days, weeks, months, years but if you use a supercomputer, it might only take minutes, hours, days, or weeks.
What does HCP type mean?
Dictionary A-Z Menu A-Z Definition Search A B C D E F G H I L M N O P R S T U V W Z Format Characters Field Length 8 Priority Mandatory Definition The healthcare professional responsible for care (HCP) is the clinician who has overall clinical responsibility for a patients healthcare during an episode. This is usually a medical consultant but may be another healthcare professional, for example a midwife, GP, nurse or Allied Healthcare Professional. Points to Note
- A separate SMR record is submitted when a patient changes Specialty, Significant Facility or Consultant/Health Care Professional Responsible for Care on medical grounds.
- Each hospital will have a list of Consultant/Healthcare Professional Responsible for Care PIN numbers appropriate to the hospital concerned. Where GPs have responsibility for patients a list of GMC numbers of the GPs concerned must be available.
- A Senior Registrar/Registrar/Specialist/Associate Specialists code number must not be used in lieu of the Consultant Code number where the clinical responsibility of care is retained by the Consultant. This may apply where patients only consult with non-consultant grade medical staff and do not see the consultant, for example SAS clinicians. For additional information please refer to this flow chart,
- A nurse/AHPs PIN number must not be used in lieu of the Consultant where the clinical responsibility of the care is retained by the consultant. Where nurses and other AHPs run clinics concurrently or separately, but the responsibility for those clinics rests with the consultant, then the activity must not be recorded on SMR00 for the nurse/AHP. This activity must only be recorded under ISD(S)1 Card Class 7 for AHPs or Card Class 9 for nurses. For additional information please refer to this flow chart,
- Where a HCP has determined/prescribed a course of treatment for a patient but has someone else deliver care on their behalf then the SMR should be attributed to the original HCP who would remain clinically responsible for care.
- However, when a HCP refers the patient to another specialty for alternative/additional treatment or care then the SMR should be attributed to the new HCP who would then be clinically responsible for the alternative/additional care.
- If an Oncologist has prescribed a course of Chemotherapy for a patient but this is delivered by a specialist nurse then the SMR should be attributed to the Consultant. SMR for Oncologist
- If an Orthopaedic Surgeon considers that the patient needs an orthotic then they would refer them to the Orthotic Team who would then determine best orthotic/treatment plan for the patient. SMR for Orthotics
- It is the NHS Board responsibility to ensure any new HCP they appoint who meets the definition above is entered in to the National Reference files to ensure records pass validation. This can be done via the eForms process, and must include the date from which the appointment is to be regarded as effective, together with the specialty/discipline or specialties/disciplines in which the HCP may work. When a HCP retires, dies or moves elsewhere, the effective end date should also be amended on the system. Details of how the add HCPs to the reference files can be found here,
- SMR00s must not be completed:- – Where a Midwifery clinic is overseen by an obstetrician – Where a nurse is carrying out routine nursing work such as bloods, dressings etc
- For SMR02 records this should reflect the person who was responsible for the care of the mother on original admission to the unit. Example 1 – If the mother was originally admitted under the care of a midwife in an Alongside Midwifery Unit (AMU) or Freestanding Midwifery Unit (FMU), then the midwife should be recorded in this section, irrespective if the mother was then transferred during her care episode. Example 2 – If the mother was originally admitted to an Obstetric Unit then the Consultant initially responsible for her care should be recorded here, irrespective of whether care was primarily provided by midwifery staff.
Further clarification on points 3&4 A SMR should be attributed to the person who is clinically responsible for care (not just for an outpatient appointment).
For example
It is important to continue recording this data item in this way to allow for comparison/trends across the years. A New data item will be introduced in due course to record the Staff Group who delivered Care, e.g. SAS, Specialist Nurse, AHP and this will pick up who is actually seeing the patient. These two data items will then complement each other, but measure two types of activity.
Recording Rules It is the Hospitals responsibility to register individuals on the National Reference Files that meet the definition of Consultant/HCP Responsible for Care as above. The 7 digit General Medical Council (GMC) Number allocated to each doctor is used as the consultant code.
The General Dental Council Number consists of D + 6 numberic. The 8 digit personal identification number (PIN) allocated to other healthcare professionals (e.g. midwives) is used as the HCP code. In the case of a midwife the PIN consists of an 8 character alpha/numeric code, although this format may differ for other HCPs (e.g.
Podiatrists). Recording GMC/GDC/PIN The code number of the HCP who had clinical responsibility for the patient during the episode should be right justified in the character spaces provided. Cross Checks
- Consultant GMC/HCP number must be present on the appropriate reference file. It is important that additions and changes are notified to ISD as soon as possible. Request Forms for updating of the Consultant/HCP reference files can be found here,
- The GMC/HCP number must be on the reference file at clinic date (record type SMR00) or Admission Date (record type SMR01, 02 and 04).
- If the record type is SMR02 and an 8 digit HCP code is used, Specialty/Discipline must be T2 or T21 (midwife).
SMR Validation – SMR Validation Related terms : Healthcare Professional Tags: professional healthcare episode consultant nurse AHP midwife GP GMC SMR00 SMR01 SMR02 SMR04 back A B C D E F G H I L M N O P R S T U V W Z
What are examples HCP?
Hexagonal Close Packed (HCP) Structure – Another common close packed structure is the hexagonal close pack. The hexagonal structure of alternating layers is shifted so its atoms are aligned to the gaps of the preceding layer. The atoms from one layer nest themselves in the empty space between the atoms of the adjacent layer just like in the fcc structure. The hcp structure has three layers of atoms. In each the top and bottom layer, there are six atoms that arrange themselves in the shape of a hexagon and a seventh atom that sits in the middle of the hexagon. The middle layer has three atoms nestle in the triangular “grooves” of the top and bottom plane.
- Note that there are six of these “grooves” surrounding each atom in the hexagonal plane, but only three of them can be filled by atoms.
- As shown in the middle image above, there are six atoms in the hcp unit cell.
- Each of the 12 atoms in the corners of the top and bottom layers contribute 1/6 atom to the unit cell, the two atoms in the center of the hexagon of both the top and bottom layers each contribute one half atom and each of the three atom in the middle layer contribute 1 atom.
The image on the right above attempts to show several hcp unit cells in a larger lattice. The coordination number of the atoms in this structure is 12. There are six nearest neighbors in the same close packed layer, three in the layer above and three in the layer below.
What are two examples of HCP?
Hexagonal Close-Packed Metals and Alloys: Processing, Microstructure and Properties Hexagonal close-packed (HCP) metals and alloys, which include titanium, zirconium, magnesium, etc., are extensively used in a variety of industrial sectors. For example, titanium and titanium alloys are widely employed in aerospace, marine, chemical engineering and biomedicine industries due to their high,
- Hexagonal close-packed (HCP) metals and alloys, which include titanium, zirconium, magnesium, etc., are extensively used in a variety of industrial sectors.
- For example, titanium and titanium alloys are widely employed in aerospace, marine, chemical engineering and biomedicine industries due to their high specific strength, high corrosion resistance and high biocompatibility; zirconium and zirconium alloys are used in the nuclear industry owing to high resistance to waterside corrosion and a low absorption cross section for thermal neutrons; magnesium and magnesium alloys receive significant attention in automobile, aerospace, and computer industries because of their low density, desirable mechanical property and thermal conductivity.Relative to face-centered cubic (FCC) and body-centered cubic (BCC) metals and alloys, HCP metals and alloys show some distinct characteristics, such as anisotropic microstructure, few slip systems, and deformation twinning due to their HCP crystal lattice structures.
As such, there is an increased need to improve the understanding of the relationships among the processing procedures, microstructures and resultant properties. Furthermore, due to various surface property requirements, surface processes are frequently applied to HCP metals and alloys.
- Research into these various surface-modification methods is still ongoing, as there are many unsolved challenges.This Research Topic aims to highlight recent advances related to the processing, microstructure and properties for hexagonal close-packed metals and alloys.
- We wish to collect a series of high-quality work on this topic to better understand the relevant mechanisms and facilitate engineering applications.
We welcome contributions addressing all aspects of HCP metals and alloys toward tackling the above considerations. As such, we welcome submissions in the form of Original Research, (Mini) Review and Perspective articles, including but not limited to the following themes:• Advanced metallurgy and manufacturing methods• Advanced processing methods• Surface modifications of HCP metals and alloys• New characterization methods• Microstructure optimization and materials design of HCP metals and alloys• Simulation and optimization of deformation or metallurgical process• New applications of HCP metals and alloys• High-performance HCP metals and alloys • Other emerging problems related to of HCP metals and alloys Important Note : All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review. : Hexagonal Close-Packed Metals and Alloys: Processing, Microstructure and Properties
What are the two types of HCP?
Hexagonal Close Packing – 
In hexagonal close packing (HCP) too, there are two basic kinds of voids are involved, namely, octahedral voids and tetrahedral voids. We know that the number of tetrahedral voids present in a lattice is twice the number of close-packed particles. While the number of octahedral voids generated is equal to the number of close-packed particles.
- The arrangement of particles in these voids depends on other factors too.
- For example, in ionic solids, the bigger ions from the close-packed structure and the smaller ions occupy the voids.
- Tetrahedral voids are occupied if the latter ions are small.
- Whereas if the latter ions are bigger, octahedral voids are occupied.
The fraction of octahedral or tetrahedral voids occupied by the molecules helps us in the determination of the formula of the compound.
What is HCP product?
From Wikipedia, the free encyclopedia Host cell proteins ( HCPs ) are process-related protein impurities that are produced by the host organism during biotherapeutic manufacturing and production. During the purification process, a majority of produced HCPs are removed from the final product (>99% of impurities removed). However, residual HCPs still remain in the final distributed pharmaceutical drug. Examples of HCPs that may remain in the desired pharmaceutical product include: monoclonal antibodies (mAbs), antibody-drug-conjugates (ADCs), therapeutic proteins, vaccines, and other protein-based biopharmaceuticals, HCPs may cause immunogenicity in individuals or reduce the potency, stability or overall effectiveness of a drug. National regulatory organisations, such as the FDA and EMA provide guidelines on acceptable levels of HCPs that may remain in pharmaceutical products before they are made available to the public. Currently, the acceptable level of HCPs in pharmaceutical drugs range from 1-100ppm (1–100 ng/mg product). However, the accepted level of HCPs in a final product is evaluated on a case-by-case basis, and depends on multiple factors including: dose, frequency of drug administration, type of drug and severity of disease. The acceptable range of HCPs in a final pharmaceutical product is large due to limitations with the detection and analytical methods that currently exist. Analysis of HCPs is complex as the HCP mixture consists of a large variety of protein species, all of which are unique to the specific host organisms, and unrelated to the intended and desired recombinant protein, Analysing these large varieties of protein species at very minute concentrations is difficult and requires extremely sensitive equipment which has not been fully developed yet. The reason that HCP levels need to be monitored is due to the uncertain effects they have on the body. At trace amounts, the effects of HCPs on patients are unknown and specific HCPs may affect protein stability and drug effectiveness, or cause immunogenicity in patients. If the stability of the drug is affected, durability of the active substance in the pharmaceutical product could decrease. The effects that the drug is intended to have on patients could also possibly be increased or decreased, leading to health complications that may arise. The degree of immunogenicity on a long-term basis is difficult, and almost impossible, to determine and consequences can include severe threats to the patient’s health.
What does HCP stand for NHS?
Consultant/HCP Responsible for Care – Priority Mandatory Definition The health professional responsible for care (HCP) is the person who carries clinical responsibility for a patient’s healthcare during an episode. This is usually a consultant but may be another healthcare professional, for example a midwife or GP.
Related terms: Healthcare professional Recording Rules The 7 digit General Medical Council (GMC) Number allocated to each doctor is used as the consultant code. The GMC number can consist of 7 numeric. The General Dental Council (GDC) Number consists of D + 6 numeric. The 8 digit personal identification number (PIN) allocated to other healthcare professionals (e.g.
midwives) is used as the HCP code. In the case of a midwife the PIN consists of an 8 character alpha/numeric code, although this format may differ for other HCPs (e.g. Podiatrists). Recording GMC/GDC/PIN The code number of the HCP who had clinical responsibility for the patient during the episode should be right justified in the character spaces provided: Note: For SMR00, enter the code number of the HCP who is responsible for the clinic.
A separate SMR record is prepared when a patient changes Specialty, Significant Facility or Consultant on medical grounds. Each hospital will have a list of Consultant/PIN numbers appropriate to the hospital concerned. Where GPs have responsibility for patients a list of GMC numbers of the GPs concerned must be available. A Senior Registrar’s or Registrar’s code number (if available to coding clerks) must not be used in lieu of the Consultant Code number. Whichever method of recording HCP is used, the Medical Records Manager must inform ISD of the appointment of any new HCP and the date from which the appointment is to be regarded as effective, together with the specialty or specialties in which the HCP may work. Request Forms for updating of the Consultant/HCP reference files can be found in here. When an HCP retires, dies or moves elsewhere, the effective date should also be notified.
Cross-Checks
Consultant GMC/HCP number must be present on the appropriate reference file. It is important that additions and changes are notified to ISD as soon as possible. Request Forms for updating of the Consultant/HCP reference files can be found here. If a 7 digit GMC number is used the Consultant must be on the reference file at clinic date (record type SMR00), date of arrival (SMR30) or Admission Date (all other record types). If an 8 digit HCP number is used the record type must be SMR00, SMR01 or SMR02. If the record type is SMR02 and an 8 digit HCP code is used Specialty/Discipline must be T2 or T21 (midwife).
Generic Definition Consultant/HCP Responsible for Care
What is HCP credentials?
From Wikipedia, the free encyclopedia Healthcare professional credentials are credentials awarded to many healthcare practitioners as a way to standardize the level of education and ability to provide care.
What is HCP in ambulance?
1. Introduction. This framework is intended for patients who require an ambulance response in a. community setting following clinical assessment by a healthcare professional. (HCP).
What does HCO mean in hospital?
Certified Health Care Organizations (HCO)
Why is HPC used?
High Performance Computing (HPC) refers to the practice of aggregating computing power in a way that delivers much higher horsepower than traditional computers and servers. HPC, or supercomputing, is like everyday computing, only more powerful. It is a way of processing huge volumes of data at very high speeds using multiple computers and storage devices as a cohesive fabric.
Why is HPC important?
What is HPC? Introduction to high-performance computing | IBM What is high-performance computing (HPC)? HPC processes massive amounts of data and solves today’s most complex computing problems in real time or near-real time. Subscribe to the IBM Newsletter HPC is technology that uses clusters of powerful processors, working in parallel, to process massive multi-dimensional datasets (big data) and solve complex problems at extremely high speeds. HPC systems typically perform at speeds more than one million times faster than the fastest commodity desktop, laptop or server systems.
- For decades the HPC system paradigm was the supercomputer, a purpose-built computer that embodies millions of processors or processor cores.
- Supercomputers are still with us; at this writing, the fastest supercomputer is the US-based (link resides outside ibm.com), with a processing speed of 1.102 exaflops, or quintillion floating point operations per second (flops).
But today, more and more organizations are running HPC solutions on clusters of high-speed computers servers, hosted on premises or in the cloud. HPC workloads uncover important new insights that advance human knowledge and create significant competitive advantage.
For example, HPC is used to sequence DNA, automate stock trading, and run algorithms and simulations—like those enabling self-driving automobiles—that analyze terabytes of data streaming from IoT sensors, radar and GPS systems in real time to make split-second decisions. A standard computing system solves problems primarily using serial computing—it divides the workload into a sequence of tasks, and then executes the tasks one after the other on the same processor.
In contrast, HPC leverages
Massively parallel computing, Parallel computing runs multiple tasks simultaneously on multiple computer servers or processors. Massively parallel computing is parallel computing using tens of thousands to millions of processors or processor cores. Computer clusters (also called HPC clusters), An HPC cluster consists of multiple high-speed computer servers networked together, with a centralized scheduler that manages the parallel computing workload. The computers, called nodes, use either high-performance multi-core CPUs or, more likely today, GPUs (graphical processing units), which are well suited for rigorous mathematical calculations, machine learning models and graphics-intensive tasks. A single HPC cluster can include 100,000 or more nodes. High-performance components: All the other computing resources in an HPC cluster—networking, memory, storage and file systems—are high-speed, high-throughput and low-latency components that can keep pace with the nodes and optimize the computing power and performance of the cluster.
As recently as a decade ago, the high cost of HPC—which involved owning or leasing a supercomputer or building and hosting an HPC cluster in an on-premises data center—put HPC out of reach for most organizations. Today HPC in the cloud—sometimes called HPC as a service, or HPCaaS—offers a significantly faster, more scalable and more affordable way for companies to take advantage of HPC.
Surging demand. Organizations across all industries are becoming increasingly dependent on the real-time insights and competitive advantage that results from solving the complex problems only HPC apps can solve. For example, credit card fraud detection—something virtually all of us rely on and most of us have experienced at one time or another—relies increasingly on HPC to identify fraud faster and reduce annoying false positives, even as fraud activity expands and fraudsters’ tactics change constantly. Prevalence of lower-latency, higher-throughput RDMA networking. RDMA—remote direct memory access—enables one networked computer to access another networked computer’s memory without involving either computer’s operating system or interrupting either computer’s processing. This helps minimize latency and maximize throughput. Emerging high-performance RDMA fabrics—including Infiniband, Virtual Interface Architecture, and RDMA over converged ethernet (RoCE)—are essentially making cloud-based HPC possible. Widespread public-cloud and private-cloud HPCaaS availability. Today every leading public cloud service provider offers HPC services. And while some organizations continue to run highly regulated or sensitive HPC workloads on-premises, many are adopting or migrating to private-cloud HPC solutions offered by hardware and solution vendors.
HPC applications have become synonymous with AI apps in general, and with machine learning and deep learning apps in particular; today most HPC systems are created with these workloads in mind. These HPC applications are driving continuous innovation in: Healthcare, genomics and life sciences.
The first attempt to sequence a human genome took 13 years ; today, HPC systems can do the job in less than a day. Other HPC applications in healthcare and life sciences include drug discovery and design, rapid cancer diagnosis, and molecular modeling. Financial services. In addition to automated trading and fraud detection (noted above), HPC powers applications in Monte Carlo simulation and other risk analysis methods.
Government and defense. Two growing HPC use cases in this area are weather forcasting and climate modeling, both of which involve processing vast amounts of historical meteorological data and millions of daily changes in climate-related data points. Other government and defense applications include energy research and intelligence work.
- Energy. In some cases overlapping with government and defense, energy-related HPC applications include seismic data processing, reservoir simulation and modeling, geospatial analytics, wind simulation and terrain mapping.
- Related solutions High performance computing on IBM Cloud Whether your workload requires a hybrid cloud environment or one contained in the cloud, IBM Cloud has the high-performance computing solution to meet your needs.
Discover HPC on IBM Cloud AI infrastructure To meet today’s challenges and prepare for the future, you need IBM AI solutions that integrate with your infrastructure and data strategy. Discover AI infrastructure solutions HPC workload management The IBM Spectrum® LSF Suites portfolio redefines cluster virtualization and workload management by providing an integrated solution for mission-critical HPC environments.
What does HPC stand for in therapy?
Hullbridge Riverside | Specialist Day Centre
Full confidential OT assessment in the privacy of your own home at a time of your convenience Full understanding of your requirements and issues you face with the aim to achieve the maximum level of independence Comprehensive written report outlining your requirements and recommending on service provision Assessment may include recommendations relating to suitable mobility or disability products or services
If you wish to discuss your or a relative’s requirement in more detail just give us a call and we can arrange a suitable time for you to talk directly to a professional Occupational Therapist about your specific needs. Your Occupational Therapist may recommend having some equipment or adaptations installed.
- This should make home life more comfortable for you and encourage you to maintain your independence.
- This, for example could be raising your armchair to make it higher and therefore easier for you to stand from.
- Assessment by an Occupational Therapist Occupational Therapists work with people who have a physical disability, a medical condition, a mental health difficulty or a learning disability.
They help individuals who have difficulties with everyday tasks, such as preparing a meal, taking a bath, going up stairs or lifting their legs into bed. The aim of occupational therapy is to enable individuals to live as independently as possible at home.
The occupational therapist can help individuals to adapt to changes in their everyday life and to overcome practical problems. They may do this by providing advice, recommending ways an everyday task can be done differently or recommending equipment or alterations for an individuals home. Occupational Therapists in independent practice How do I know if an Occupational Therapist is properly registered? All occupational therapists are required to register with the Health Professionals Council (HPC) regulatory body.
The HPC is responsible for the conduct, performance and ethical behaviour of its registrants. Visit the HPC website to check the registration status of an Occupational Therapist. : Hullbridge Riverside | Specialist Day Centre
What does HCP stand for NHS?
Consultant/HCP Responsible for Care – Priority Mandatory Definition The health professional responsible for care (HCP) is the person who carries clinical responsibility for a patient’s healthcare during an episode. This is usually a consultant but may be another healthcare professional, for example a midwife or GP.
Related terms: Healthcare professional Recording Rules The 7 digit General Medical Council (GMC) Number allocated to each doctor is used as the consultant code. The GMC number can consist of 7 numeric. The General Dental Council (GDC) Number consists of D + 6 numeric. The 8 digit personal identification number (PIN) allocated to other healthcare professionals (e.g.
midwives) is used as the HCP code. In the case of a midwife the PIN consists of an 8 character alpha/numeric code, although this format may differ for other HCPs (e.g. Podiatrists). Recording GMC/GDC/PIN The code number of the HCP who had clinical responsibility for the patient during the episode should be right justified in the character spaces provided: Note: For SMR00, enter the code number of the HCP who is responsible for the clinic.
A separate SMR record is prepared when a patient changes Specialty, Significant Facility or Consultant on medical grounds. Each hospital will have a list of Consultant/PIN numbers appropriate to the hospital concerned. Where GPs have responsibility for patients a list of GMC numbers of the GPs concerned must be available. A Senior Registrar’s or Registrar’s code number (if available to coding clerks) must not be used in lieu of the Consultant Code number. Whichever method of recording HCP is used, the Medical Records Manager must inform ISD of the appointment of any new HCP and the date from which the appointment is to be regarded as effective, together with the specialty or specialties in which the HCP may work. Request Forms for updating of the Consultant/HCP reference files can be found in here. When an HCP retires, dies or moves elsewhere, the effective date should also be notified.
Cross-Checks
Consultant GMC/HCP number must be present on the appropriate reference file. It is important that additions and changes are notified to ISD as soon as possible. Request Forms for updating of the Consultant/HCP reference files can be found here. If a 7 digit GMC number is used the Consultant must be on the reference file at clinic date (record type SMR00), date of arrival (SMR30) or Admission Date (all other record types). If an 8 digit HCP number is used the record type must be SMR00, SMR01 or SMR02. If the record type is SMR02 and an 8 digit HCP code is used Specialty/Discipline must be T2 or T21 (midwife).
Generic Definition Consultant/HCP Responsible for Care
What does HCP mean in palliative care?
7 – 10. This approach involves the patient as the centre of care, emphasizing a multi-professional team approach, and healthcare professionals (HCPs) being respectful and responsive to patients’ and their families’ life situation, preferences, needs and values.4, 11, 12.
What is HCP in ambulance?
1. Introduction. This framework is intended for patients who require an ambulance response in a. community setting following clinical assessment by a healthcare professional. (HCP).
What does HCP stand for diabetes?
Introduction – Diabetes mellitus is a chronic metabolic disease associated with serious complications and high healthcare cost, affecting 1 in 5 adults 65 years and above worldwide ( 1 ). Older patients with diabetes are at risk of developing vascular complications, due to a longer disease duration and decline of physiological reserve ( 2 ).
These complications include retinopathy, nephropathy, neuropathy and heart diseases ( 3 ) which can negatively impact the quality of life and deepen the cost burden of disease. In Singapore where this study was conducted, the prevalence of diabetes (14.2%) had surpassed the global average (9.3%) in 2019 ( 1 ), and is projected to reach 25% in 2050 ( 4 ).
Type 2 diabetes (T2DM) accounts for 99% of all diagnosed cases of diabetes ( 5 ). The lifetime medical expenditure of patients with diabetes was shown to be 5.6 times higher than that of patients with non-diabetes ( 6 ). Nationally, healthcare spending for diabetes is estimated to increase from US$787 million in 2010 to US$1,867 million in 2050 ( 7 ).
The increased socioeconomic burden associated with diabetes underscores the importance of early intervention to prevent and delay the complications resulting from the disease. Diabetes self-management is defined as an active participation of health-seeking behaviors and activities by patients, to attain good glycemic control and reduce complications ( 8, 9 ).
The strategies for self-management include lifestyle modification (healthy diet, physical activity, weight loss) ( 10, 11 ), psychosocial support ( 12 ), education on self-management ( 13, 14 ) and use of mobile technology ( 15 – 17 ). Lifestyle modification is the first-line treatment for diabetes mellitus and has been shown to be more effective than pharmacotherapy ( 10, 11 ), However, lifestyle modification requires significant commitments and motivation on the part of patients to sustain behavior changes ( 18 ).
A novel model of care that takes advantage of mobile health (mHealth) technology has been found to be effective in increasing patients’ interest and motivation for lifestyle modification ( 19 ). A growing body of literature also suggests that setting personalized goals, supporting self-monitoring and providing feedback on alterations in diet and physical activities through mHealth apps enhanced the ability of patient with diabetes for self-management ( 20 – 22 ).
Perspectives of healthcare professionals (HCPs) are pivotal to co-development of self-management strategies for patients with diabetes as HCPs can act as an enabler to empower patients through shared understanding and partnership. Existing literature reported common barriers faced by HCPs which include patient-related factors (motivation, health literacy, time constraints, finances, comorbidity, cultural differences) and HCP-related factors (heavy workload, poor patient-provider relationship) ( 23 – 27 ).
In addition to barriers to self-management in adult patients with diabetes, recent systematic reviews highlighted that coping skills, relationship with family and peers and diabetes education may enable or hamper effective self-management in families with children and adolescents with diabetes ( 28, 29 ).
Although existing studies have offered a significant insight into the factors influencing diabetes self-management, they have been largely limited to the perspectives of patients within the context of a Western healthcare setting. In addition, there is a paucity of research on perceptions of HCPs regarding potential values and utility of a mHealth application and its features in fostering self-management and improving quality care for patients with diabetes.
- This study aims to explore the factors influencing self-management in adult patients with diabetes from the perspectives of HCPs in a multi-ethnic Asian healthcare setting.
- We also sought to understand the HCP’s perceptions of and attitudes to a mobile health (mHealth) application and its features for self-management.
Findings from this study will inform the design of an optimal mHealth intervention that can foster self-management and address the needs of HCPs in caring of adult patients with diabetes.